Head to Head Analysis: Bristol Myers Squibb (NYSE:BMY) vs. Orion OYJ (OTCMKTS:ORINY)

Bristol Myers Squibb (NYSE:BMY) and Orion OYJ (OTCMKTS:ORINY) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Bristol Myers Squibb and Orion OYJ’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Orion OYJ	28.52%	50.37%	30.65%

Dividends

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.1%. Orion OYJ pays an annual dividend of $0.38 per share and has a dividend yield of 0.8%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Orion OYJ pays out 15.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Bristol Myers Squibb and Orion OYJ, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1	10	13	1	2.56
Orion OYJ	0	1	1	0	2.50

Bristol Myers Squibb currently has a consensus price target of $67.06, indicating a potential upside of 10.17%. Given Bristol Myers Squibb’s stronger consensus rating and higher probable upside, analysts plainly believe Bristol Myers Squibb is more favorable than Orion OYJ.

Volatility & Risk

Bristol Myers Squibb has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Orion OYJ has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500.

Institutional and Insider Ownership

76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Bristol Myers Squibb and Orion OYJ”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$49.19 billion	2.53	$7.05 billion	$4.54	13.41
Orion OYJ	$2.14 billion	6.23	$566.04 million	$2.43	19.41

Bristol Myers Squibb has higher revenue and earnings than Orion OYJ. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Orion OYJ, indicating that it is currently the more affordable of the two stocks.

Summary

Bristol Myers Squibb beats Orion OYJ on 13 of the 18 factors compared between the two stocks.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.